Want to see IN:SHARDACROP full AI Analyst Report?
Top Page
Sharda Cropchem Ltd.
(SHARDACROP)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹870.00
▲(10.51% Upside)
Action:Reiterated
Date:08/17/26
The score is supported primarily by strong financial performance (debt-free balance sheet and FY2026 profitability/ROE rebound) and reasonable valuation (low P/E with a modest dividend). This is meaningfully offset by weak technical signals, with the price below major moving averages and negative momentum indicators.
Positive Factors
Debt-Free Balance Sheet
Effectively zero leverage reduces interest burden and refinancing exposure, preserving flexibility to fund registrations, inventory and market expansion. The stronger FY2026 ROE also indicates that the balance sheet is currently supporting efficient capital use.
Negative Factors
Cyclical Earnings Volatility
The sharp FY2024 downturn and subsequent recovery demonstrate meaningful sensitivity to agricultural cycles, input costs and market conditions. Such variability makes future margins and returns less predictable even when the underlying product portfolio remains diversified.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
Effectively zero leverage reduces interest burden and refinancing exposure, preserving flexibility to fund registrations, inventory and market expansion. The stronger FY2026 ROE also indicates that the balance sheet is currently supporting efficient capital use.
Read all positive factors
Sharda Cropchem Ltd. (SHARDACROP) vs. iShares MSCI India ETF (INDA)
Market Cap
₹69.11B
Dividend Yield1.96%
Average Volume (3M)8.71K
Price to Earnings (P/E)11.0
Beta (1Y)1.81
Revenue Growth18.52%
EPS Growth49.11%
CountryIN
Employees500
SectorGeneral
Sector StrengthN/A
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)69.41
Shares Outstanding90,220,500
10 Day Avg. Volume5,988
30 Day Avg. Volume8,709
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)2.50
Price to Sales (P/S)1.49
P/FCF Ratio11.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)74.85
Revenue Forecast (FY)₹59.86B
Sharda Cropchem Ltd. Business Overview & Revenue Model
Company Description
Founded in 1987 and headquartered in Mumbai, India, Sharda Cropchem Limited is a prominent global supplier of crop protection chemicals. The company offers an extensive portfolio of agrochemical products, including various formulations and generic...
How the Company Makes Money
Sharda Cropchem makes money primarily by selling agrochemical products (largely off‑patent/generic crop protection chemicals) in the markets where it holds the required regulatory registrations and has established distribution channels. Its revenu...
Sharda Cropchem Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.57B | 52.68B | 43.20B | 31.61B | 40.45B | 35.76B |
| Gross Profit | 16.37B | 14.99B | 12.92B | 8.18B | 11.84B | 10.76B |
| EBITDA | 11.72B | 10.51B | 6.13B | 3.43B | 6.99B | 7.25B |
| Net Income | 6.26B | 6.81B | 3.04B | 318.83M | 3.42B | 3.49B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 57.80B | 47.25B | 40.38B | 43.51B | 37.43B |
| Cash, Cash Equivalents and Short-Term Investments | 7.02B | 5.81B | 5.57B | 3.74B | 2.13B | 1.96B |
| Total Debt | 0.00 | 32.67M | 77.60M | 183.00M | 29.65M | 466.48M |
| Total Liabilities | -31.37B | 26.43B | 22.24B | 18.01B | 21.18B | 18.30B |
| Stockholders Equity | 31.37B | 31.36B | 25.01B | 22.37B | 22.32B | 19.12B |
Cash Flow | ||||||
| Free Cash Flow | 6.05B | 6.78B | 6.03B | 692.08M | 842.03M | 333.12M |
| Operating Cash Flow | 6.05B | 6.79B | 6.04B | 3.41B | 3.28B | 2.67B |
| Investing Cash Flow | -5.24B | -5.37B | -5.10B | -3.93B | -1.45B | -2.08B |
| Financing Cash Flow | -593.39M | -1.17B | -679.32M | -369.10M | -971.01M | -909.56M |
Sharda Cropchem Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹69.11B | 11.03 | ― | 1.96% | 18.52% | 49.11% | |
68 Neutral | ₹178.87B | 24.40 | ― | 3.77% | -2.78% | 23.56% | |
65 Neutral | ₹43.70B | 16.48 | ― | 0.20% | -5.63% | -11.38% | |
58 Neutral | ₹484.43B | 23.94 | ― | 1.05% | 12.86% | 72.26% | |
57 Neutral | ₹39.28B | 18.38 | ― | 1.49% | 4.41% | 24.42% | |
56 Neutral | ₹342.50B | 29.41 | ― | 0.44% | -16.57% | -27.71% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:SHARDACROP
Sharda Cropchem Ltd.
766.05
-108.26
-12.38%
IN:BAYERCROP
Bayer Cropscience India Limited
3,980.00
-955.63
-19.36%
IN:DHANUKA
Dhanuka Agritech Limited
980.30
-573.21
-36.90%
IN:PIIND
PI Industries Limited
2,257.50
-1,446.34
-39.05%
IN:RALLIS
Rallis India Limited
202.00
-130.34
-39.22%
IN:UPL
UPL Limited
573.85
-113.15
-16.47%
Sharda Cropchem Ltd. Corporate Events
Sharda Cropchem Board Clears Q1 FY27 Unaudited Results After Limited Review
Jul 29, 2026
Sharda Cropchem Ltd. announced that its board met on July 29, 2026 and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in line with SEBI’s listing and disclosure regulations. The resu...
Sharda Cropchem publishes Q1 FY2026 investor presentation
Jul 29, 2026
Sharda Cropchem Ltd. has released an investor and analyst presentation detailing its unaudited financial results for the quarter ended June 30, 2026, and submitted it to both the NSE and BSE. The presentation has also been uploaded to the company&...
Sharda Cropchem Posts Revenue and Margin Growth Amid Mixed Regional Performance in Q1 FY27
Jul 29, 2026
Sharda Cropchem Ltd. reported unaudited consolidated financial results for the quarter ended June 30, 2026, showing revenue growth of 9% year-on-year to Rs. 1,074 crore and a 25% rise in EBITDA to Rs. 178 crore, with margins improving to 16.6%. De...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.